Aurobindo Pharma: Amalgamation/Merger of Auroactive Pharma Private Limited with Apitoria Pharma Private Limited wholly owned…
Aurobindo Pharma (AUROPHARMA) filed a disclosure titled "Amalgamation/Merger of Auroactive Pharma Private Limited with Apitoria Pharma Private Limited wholly owned subsidiaries of the Company". The company is valued at about ₹98,102 crore.
What happened
Aurobindo Pharma (AUROPHARMA) filed a disclosure with the exchanges on 4 November 2026 at 08:25 PM titled "Amalgamation/Merger of Auroactive Pharma Private Limited with Apitoria Pharma Private Limited wholly owned subsidiaries of the Company".
From the filing: "Aurobindo Pharma Limited has informed the Exchange about Amalgamation/Merger of Auroactive Pharma Private Limited with Apitoria Pharma Private Limited wholly owned subsidiaries of the Company."
Company snapshot
Aurobindo Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹98,102 crore.
The stock last traded at ₹1,705, against a 52-week range of ₹1,106–₹1,740 (2.0% below the high).
Before this filing the shares had moved +1.1% over the month and +6.8% over three months. Average daily turnover over the last 20 sessions was about ₹137 crore.
Promoters held 51.88% at the end of Q1 FY27, up 0.06% points from the previous quarter; 13.75% of promoter shares were pledged. Foreign institutions owned 16.38% and domestic institutions 25.10%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 7,868 | 824.8 | 14.2 |
| Q2 FY26 | 8,286 | 848.5 | 14.61 |
| Q3 FY26 | 8,646 | 910.3 | 15.67 |
| Q4 FY26 | 8,853 | 921.3 | 15.86 |
| Q1 FY27 | 9,150 | 1,032.6 | 17.86 |
What history shows
This is not the company's first m&a disclosure: BCEIE has at least 12 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 0.2% on average the next trading day and was up 2.2% on average after five days (11 filings with price data).
Across 150 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +0.9% over five days; 59% of them rose the next day.
Market-wide, 2,343 m&a filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 2 Oct 2026 | Completion of acquisition. | +1.0% | +1.8% |
| 2 Oct 2026 | M&A | +1.0% | +1.8% |
| 1 Oct 2026 | M&A | +0.2% | — |
| 12 Sept 2026 | M&A | −1.2% | +2.0% |
| 1 Sept 2026 | Incorporation of a new wholly owned subsidiary by the name of… | −4.0% | −1.5% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
- 4 November 2026: Board meeting — Financial Results/Dividend.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.